Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide

References

• Chasis H , Jolliffe N , Smith HW . The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man. J Clin Invest . 1933;12(6):1083–1090. doi:10.1172/jci100559 16694183
   PubMedGoogle Scholar
• Himsworth HP . The relation of glycosuria to glycaemia and the determination of the renal threshold for glucose. Biochem J . 1931;25(4):1128–1146. doi:10.1042/bj0251128 16744677
   PubMedGoogle Scholar
• Wright EM , Hirayama BA , Loo DF . Active sugar transport in health and disease. J Intern Med . 2007;261(1):32–43. doi:10.1111/j.1365-2796.2006.01746.x 17222166
   PubMed Web of Science ®Google Scholar
• Kimmich GA , Randles J . Sodium-sugar coupling stoichiometry in chick intestinal cells. Am J Physiol Cell Physiol . 1984;247:1. doi:10.1152/ajpcell.1984.247.1.c74
   Web of Science ®Google Scholar
• Mueckler M , Thorens B . The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med . 2013;34(2–3):121–138. doi:10.1016/j.mam.2012.07.001 23506862
   PubMed Web of Science ®Google Scholar
• Gallo LA , Wright EM , Vallon V . Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diabetes Vasc Dis Res . 2015;12(2):78–89. doi:10.1177/1479164114561992
   PubMed Web of Science ®Google Scholar
• Wright EM , Loo DDF , Hirayama BA . Biology of human sodium glucose transporters. Physiol Rev . 2011;91(2):733–794. doi:10.1152/physrev.00055.2009 21527736
   PubMed Web of Science ®Google Scholar
• Wright EM , Turk E . The sodium/glucose cotransport family SLC5. Pflugers Archiv Eur J Physiol . 2004;447(5):510–518. doi:10.1007/s00424-003-1063-6 12748858
   PubMed Web of Science ®Google Scholar
• Nishimura M , Naito S . Tissue-specific mRNA Expression Profiles of Human ATP-binding Cassette and Solute Carrier Transporter Superfamilies. Drug Metab Pharmacokinet . 2005;20(6):452–477. doi:10.2133/dmpk.20.452 16415531
   PubMedGoogle Scholar
• Quamme GA , Freeman HJ . Evidence for a high-affinity sodium-dependent D-glucose transport system in the kidney. Am J Physiol Renal Physiol . 1987;253:1. doi:10.1152/ajprenal.1987.253.1.f151
   Web of Science ®Google Scholar
• Turner RJ , Moran A . Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule: evidence from vesicle studies. Am J Physiol Renal Physiol . 1982;242:4. doi:10.1152/ajprenal.1982.242.4.f406
   Web of Science ®Google Scholar
• Santer R . Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol . 2003;14(11):2873–2882. doi:10.1097/01.asn.0000092790.89332.d2 14569097
   PubMed Web of Science ®Google Scholar
• Vallon V , Platt KA , Cunard R , et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol . 2010;22(1):104–112. doi:10.1681/asn.2010030246 20616166
   PubMed Web of Science ®Google Scholar
• Hummel CS , Lu C , Loo DDF , et al. Glucose transport by human renal Na/d-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol . 2011;300:1. doi:10.1152/ajpcell.00388.2010
   Web of Science ®Google Scholar
• Komoroski B , Vachharajani N , Boulton D , et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther . 2009;85(5):520–526. doi:10.1038/clpt.2008.251 19129748
   PubMed Web of Science ®Google Scholar
• Ghezzi C , Loo DDF , Wright EM . Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia . 2018;61(10):2087–2097. doi:10.1007/s00125-018-4656-5 30132032
   PubMed Web of Science ®Google Scholar
• Oku A , Ueta K , Arakawa K , et al. T-1095, an inhibitor of renal Na -glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes . 1999;48(9):1794–1800. doi:10.2337/diabetes.48.9.1794 10480610
   PubMed Web of Science ®Google Scholar
• Link J , Sorensen BK . A method for preparing C-glycosides related to phlorizin. Tetrahedron Lett . 2000;41(48):9213–9217. doi:10.1016/s0040-4039(00)01709-3
   Web of Science ®Google Scholar
• Crane RK , Miller D , Bihler I . The restrictions on possible mechanisms of intestinal active transport of sugars. In: Kleinzeller A, Kotyk A, editors. Membr Transport Metab . 1961:439–449.
   Google Scholar
• Hediger MA , Coady MJ , Ikeda TS , Wright EM . Expression cloning and cDNA sequencing of the Na/glucose co-transporter. Nature . 1987;330(6146):379–381. doi:10.1038/330379a0 2446136
   PubMed Web of Science ®Google Scholar
• Wright EM , Ghezzi C , Loo DDF . Novel and Unexpected Functions of SGLTs. Physiology . 2017;32(6):435–443. doi:10.1152/physiol.00021.2017 29021363
   PubMed Web of Science ®Google Scholar
• Bisignano P , Ghezzi C , Jo H , et al. Inhibitor binding mode and allosteric regulation of Na -glucose symporters. Nat Commun . 2018;9:1. doi:10.1038/s41467-018-07700-1 29317637
   PubMed Web of Science ®Google Scholar
• Ghezzi C , Hirayama BA , Gorraitz E , et al. SGLT2 inhibitors act from the extracellular surface of the cell membrane. Phys Rep . 2014;2:6. doi:10.14814/phy2.12058
   Google Scholar
• Grempler R , Thomas L , Eckhardt M , et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obesity Metab . 2011;14(1):83–90. doi:10.1111/j.1463-1326.2011.01517.x
   Web of Science ®Google Scholar
• Isaji M . SGLT2 inhibitors: molecular design and potential differences in effect. Kidney Int . 2011;79 (Suppl 120):S14–S19. doi:10.1038/ki.2010.511
   Web of Science ®Google Scholar
• Zinman B , Wanner C , Lachin JM , et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med . 2015;373(22):2117–2128. doi:10.1056/nejmoa1504720 26378978
   PubMed Web of Science ®Google Scholar
• Perkovic V , Zeeuw DD , Mahaffey KW , et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS program randomised clinical trials. Lancet Diabetes Endocrinol . 2018;6(9):691–704. doi:10.1016/s2213-8587(18)30141-4 29937267
   PubMed Web of Science ®Google Scholar
• Zaccardi F , Webb DR , Htike ZZ , et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obesity Metab . 2016;18(8):783–794. doi:10.1111/dom.12670
   PubMed Web of Science ®Google Scholar
• Wiviott SD , Raz I , Bonaca MP , et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med . 2019;380(4):347–357. doi:10.1056/nejmoa1812389 30415602
   PubMed Web of Science ®Google Scholar
• Neal B , Perkovic V , Mahaffey KW , et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med . 2017;377(7):644–657. doi:10.1056/nejmoa1611925 28605608
   PubMed Web of Science ®Google Scholar
• Khouri C , Cracowski J-L, Roustit M . SGLT-2 inhibitors and the risk of lower-limb amputation: is this a class effect? Diabetes Obesity Metab . 2018;20(6):1531–1534. doi:10.1111/dom.13255
   PubMed Web of Science ®Google Scholar
• Verma S , Jüni P , Mazer CD . Pump, pipes, and filter: do SGLT2 inhibitors cover it all? Lancet . 2019;393(10166):3–5. doi:10.1016/s0140-6736(18)32824-1 30424891
   PubMed Web of Science ®Google Scholar
• Zelniker TA , Wiviott SD , Raz I , et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet . 2019;393(10166):31–39. doi:10.1016/s0140-6736(18)32590-x 30424892
   PubMed Web of Science ®Google Scholar
• Standards of Medical Care in Diabetes—2019. Abridged for Primary Care Providers. Clin Diabetes . 2018;37(1):11–34. doi:10.2337/cd18-0105
   Google Scholar
• Terra SG , Focht K , Davies M , et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obesity Metab . 2017;19(5):721–728. doi:10.1111/dom.12888
   PubMed Web of Science ®Google Scholar
• Roden M , Weng J , Eilbracht J , et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol . 2013;1(3):208–219. doi:10.1016/s2213-8587(13)70084-6 24622369
   PubMed Web of Science ®Google Scholar
• Roden M , Merker L , Christiansen AV , et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a phase III randomized controlled trial. Cardiovasc Diabetol . 2015;14:1. doi:10.1186/s12933-015-0314-0 25582325
   PubMed Web of Science ®Google Scholar
• Phung OJ , Sobieraj DM , Engel SS , et al. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obesity Metab . 2013;16(5):410–417. doi:10.1111/dom.12233
   Web of Science ®Google Scholar
• Milder T , Stocker S , Shaheed CA , et al. Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes: a systematic review and meta-analysis. J Clin Med . 2019;8(1):45. doi:10.3390/jcm8010045
   Web of Science ®Google Scholar
• Pawaskar M , Bilir SP , Kowal S , et al. Cost-effectiveness of intensification with sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom. Diabetes Obesity Metab . 2019;21(4):1010–1017. doi:10.1111/dom.13618
   Web of Science ®Google Scholar
• Mcmurray J . EMPA-REG – the “diuretic hypothesis.”. J Diabetes Complications . 2016;30(1):3–4. doi:10.1016/j.jdiacomp.2015.10.012 26597600
   PubMed Web of Science ®Google Scholar
• Lee H-C , Shiou Y-L , Jhuo S-J , et al. The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovasc Diabetol . 2019;18:1. doi:10.1186/s12933-019-0849-6 30626440
   PubMed Web of Science ®Google Scholar
• Mordi NA , Mordi IR , Singh JS , et al. Renal and cardiovascular effects of sodium–glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial. BMJ Open . 2017;7:10. doi:10.1136/bmjopen-2017-018097
   Web of Science ®Google Scholar
• Cavender MA , Norhammar A , Birkeland KI , et al. SGLT-2 inhibitors and cardiovascular risk. J Am Coll Cardiol . 2018;71(22):2497–2506. doi:10.1016/j.jacc.2018.01.085 29852973
   PubMed Web of Science ®Google Scholar
• Kato ET , Silverman MG , Mosenzon O , et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation . 2019;139(22):2528–2536. doi:10.1161/circulationaha.119.040130 30882238
   PubMed Web of Science ®Google Scholar
• Verma S , Mcmurray JJV , Cherney DZI . The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition. JAMA Cardiol . 2017;2(9):939. doi:10.1001/jamacardio.2017.1891 28636701
   PubMed Web of Science ®Google Scholar
• Verma S , Mcmurray JJV . SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia . 2018;61(10):2108–2117. doi:10.1007/s00125-018-4670-7 30132036
   PubMed Web of Science ®Google Scholar
• Verma S , Mcmurray JJ . The serendipitous story of SGLT2 inhibitors in heart failure. Circulation . 2019;139(22):2537–2541. doi:10.1161/circulationaha.119.040514 30882236
   PubMed Web of Science ®Google Scholar
• Tikkanen I , Narko K , Zeller C , et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care . 2015;38(3):420–428. doi:10.2337/dc14-1096 25271206
   PubMed Web of Science ®Google Scholar
• Vasilakou D , Karagiannis T , Athanasiadou E , et al. Sodium–glucose cotransporter 2 inhibitors for type 2 diabetes. Ann Intern Med . 2013;159(4):262. doi:10.7326/0003-4819-159-4-201308200-00007 24026259
   PubMed Web of Science ®Google Scholar
• Park SW , Goodpaster BH , Lee JS , et al. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care . 2009;32(11):1993–1997. doi:10.2337/dc09-0264 19549734
   PubMed Web of Science ®Google Scholar
• Özdirenç M , Biberoğlu S , Özcan A . Evaluation of physical fitness in patients with Type 2 diabetes mellitus. Diabetes Res Clin Pract . 2003;60(3):171–176. doi:10.1016/s0168-8227(03)00064-0 12757989
   PubMed Web of Science ®Google Scholar
• Regensteiner JG , Bauer TA , Reusch JE . Rosiglitazone improves exercise capacity in individuals with type 2 diabetes. Diabetes Care . 2005;28(12):2877–2883. doi:10.2337/diacare.28.12.2877 16306548
   PubMed Web of Science ®Google Scholar
• Kadoglou NPE , Iliadis F , Angelopoulou N , et al. Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with type 2 diabetes mellitus. Diabetic Med . 2008;25(3):333–340. doi:10.1111/j.1464-5491.2007.02375.x 18307460
   PubMed Web of Science ®Google Scholar
• Lepore JJ , Olson E , Demopoulos L , et al. Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction. JACC . 2016;4(7):559–566. doi:10.1016/j.jchf.2016.01.008 27039125
   PubMedGoogle Scholar
• Núñez J , Palau P , Domínguez E , et al. Early effects of empagliflozin on exercise tolerance in patients with heart failure: a pilot study. Clin Cardiol . 2018;41(4):476–480. doi:10.1002/clc.22899 29663436
   PubMed Web of Science ®Google Scholar
• Carbone S , Canada JM , Billingsley HE , et al. Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics. Diabetes Obesity Metab . 2018;20(8):2014–2018. doi:10.1111/dom.13309
   PubMed Web of Science ®Google Scholar
• EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol . 2016;64(6):1388–1402. doi:10.1016/j.jhep.2015.11.004 27062661
   PubMed Web of Science ®Google Scholar
• Saponaro C , Gaggini M , Gastaldelli A . Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms. Curr Diab Rep . 2015;15:6. doi:10.1007/s11892-015-0607-4
   Web of Science ®Google Scholar
• Younossi ZM , Koenig AB , Abdelatif D , et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology . 2016;64:73–84. doi:10.1002/hep.28431 26707365
   PubMed Web of Science ®Google Scholar
• Seko Y , Sumida Y , Tanaka S , et al. Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients. Hepatol Res . 2014;45:10. doi:10.1111/hepr.12456 24606181
   PubMed Web of Science ®Google Scholar
• Seko Y , Nishikawa T , Umemura A , et al. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis. Diabetes Metab Syndrome Obesity . 2018;(2018(11):835–843. doi:10.2147/dmso.s184767
   Web of Science ®Google Scholar
• Kabil SL , Mahmoud NM . Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation. Eur J Pharmacol . 2018;828:135–145. doi:10.1016/j.ejphar.2018.03.043 29608898
   PubMed Web of Science ®Google Scholar
• Ferrannini G , Hach T , Crowe S , Sanghvi A , Hall KD , Ferrannini E . Energy balance after sodium–glucose cotransporter 2 inhibition. Diabetes Care . 2015;38(9):1730–1735. doi:10.2337/dc15-0355 26180105
   PubMed Web of Science ®Google Scholar
• He YL , Haynes W , Meyers CD , et al. The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes. Diabetes Obesity Metab . 2019. doi:10.1111/dom.13654
   Web of Science ®Google Scholar
• Scafoglio CR , Villegas B , Abdelhady G , et al. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci Transl Med . 2018;10:467. doi:10.1126/scitranslmed.aat5933
   Web of Science ®Google Scholar
• Jardiance (empagliflozin tablets, for oral use) [package Insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2018.
   Google Scholar
• Invokana (canagliflozin tablets, for oral use) [package Insert] . Titusvlle, NJ: Janssen Pharmaceuticals, Inc.; 2018.
   Google Scholar
• Farixga (dapagliflozin tablets, for oral use) [package Insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.
   Google Scholar
• Steglatro (ertugliflozin tablets, for oral use) [package Insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; 2018.
   Google Scholar
• Dryden M , Baguneid M , Eckmann C , et al. Pathophysiology and burden of infection in patients with diabetes mellitus and peripheral vascular disease: focus on skin and soft-tissue infections. Clin Microbiol Infect . 2015;21. doi:10.1016/j.cmi.2015.03.024
   Web of Science ®Google Scholar
• Geerlings SE . Urinary tract infections in patients with diabetes mellitus: epidemiology, pathogenesis and treatment. Int J Antimicrob Agents . 2008;31:54–57. doi:10.1016/j.ijantimicag.2007.07.042
   PubMed Web of Science ®Google Scholar
• Shah BR , Hux JE . Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care . 2003;26(2):510–513. doi:10.2337/diacare.26.2.510 12547890
   PubMed Web of Science ®Google Scholar
• Benfield T , Jensen JS , Nordestgaard BG . Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia . 2006;50(3):549–554. doi:10.1007/s00125-006-0570-3 17187246
   PubMed Web of Science ®Google Scholar
• Scheen AJ . An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf . 2019. doi:10.1080/14740338.2019.1602116
   Web of Science ®Google Scholar
• Johnsson KM , Ptaszynska A , Schmitz B , et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications . 2013;27(5):479–484. doi:10.1016/j.jdiacomp.2013.04.012 23806570
   PubMed Web of Science ®Google Scholar
• Bailey CJ , Gross JL , Pieters A , et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet . 2010;375(9733):2223–2233. doi:10.1016/s0140-6736(10)60407-2 20609968
   PubMed Web of Science ®Google Scholar
• Bode B , Stenlöf K , Harris S , et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obesity Metab . 2015;17(3):294–303. doi:10.1111/dom.12428
   PubMed Web of Science ®Google Scholar
• Tanaka A , Node K . Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit? Cardiovasc Diabetol . 2017;16(1). doi:10.1186/s12933-017-0611-x
   Web of Science ®Google Scholar
• Kaneko M , Narukawa M . Effects of sodium-glucose cotransporter 2 inhibitors on amputation, bone fracture, and cardiovascular outcomes in patients with type 2 diabetes mellitus using an alternative measure to the hazard ratio. Clin Drug Investig . 2018;39(2):179–186. doi:10.1007/s40261-018-0731-4
   Web of Science ®Google Scholar
• Kohler S , Zeller C , Iliev H , et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I–III clinical trials. Adv Ther . 2017;34(7):1707–1726. doi:10.1007/s12325-017-0573-0 28631216
   PubMed Web of Science ®Google Scholar
• Chang H-Y , Singh S , Mansour O , et al. Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes. JAMA Intern Med . 2018;178(9):1190–1198. doi:10.1001/jamainternmed.2018.3034 30105373
   PubMed Web of Science ®Google Scholar
• Janghorbani M , Dam RMV , Willett WC , et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol . 2007;166(5):495–505. doi:10.1093/aje/kwm106 17575306
   PubMed Web of Science ®Google Scholar
• Vestergaard P . Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporosis Int . 2006;18(4):427–444. doi:10.1007/s00198-006-0253-4
   Web of Science ®Google Scholar
• Ma L , Oei L , Jiang L , et al. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol . 2012;27(5):319–332. doi:10.1007/s10654-012-9674-x 22451239
   PubMed Web of Science ®Google Scholar
• Thrailkill KM , Nyman JS , Bunn RC , et al. The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes. Bone . 2017;94:141–151. doi:10.1016/j.bone.2016.10.026 27989651
   PubMed Web of Science ®Google Scholar
• Thrailkill KM , Bunn RC , Nyman JS , et al. SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice. Bone . 2016;82:101–107. doi:10.1016/j.bone.2015.07.025 26211996
   PubMed Web of Science ®Google Scholar
• Bilezikian JP , Watts NB , Usiskin K , et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab . 2016;101(1):44–51. doi:10.1210/jc.2015-1860 26580234
   PubMed Web of Science ®Google Scholar
• Kohan DE , Fioretto P , Tang W , et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int . 2014;85(4):962–971. doi:10.1038/ki.2013.356 24067431
   PubMed Web of Science ®Google Scholar
• Watts NB , Bilezikian JP , Usiskin K , et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab . 2016;101(1):157–166. doi:10.1210/jc.2015-3167 26580237
   PubMed Web of Science ®Google Scholar
• Ruanpeng D , Ungprasert P , Sangtian J , et al. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Metab Res Rev . 2017;33:6. doi:10.1002/dmrr.2903
   Web of Science ®Google Scholar
• Tang H , Zhang X , Zhang J , et al. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. Diabetologia . 2016;59(12):2546–2551. doi:10.1007/s00125-016-4101-6 27628105
   PubMed Web of Science ®Google Scholar
• Forst T , Guthrie R , Goldenberg R , et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obesity Metab . 2014;16(5):467–477. doi:10.1111/dom.12273
   PubMed Web of Science ®Google Scholar
• Weir MR , Kline I , Xie J , et al. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin . 2014;30(9):1759–1768. doi:10.1185/03007995.2014.919907 24786834
   PubMed Web of Science ®Google Scholar
• Taylor SI , Blau JE , Rother KI . Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol . 2015;3(1):8–10. doi:10.1016/s2213-8587(14)70227-x 25523498
   PubMed Web of Science ®Google Scholar
• Linfoot P , Bergstrom C , Ipp E . Pathophysiology of ketoacidosis in Type 2 diabetes mellitus. Diabetic Med . 2005;22(10):1414–1419. doi:10.1111/j.1464-5491.2005.01660.x 16176205
   PubMed Web of Science ®Google Scholar
• Daniele G , Xiong J , Solis-Herrera C , et al. Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. Diabetes Care . 2016;39(11):2036–2041. doi:10.2337/dc15-2688 27561923
   PubMed Web of Science ®Google Scholar
• Perry RJ , Rabin-Court A , Song JD , et al. Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats. Nat Commun . 2019;10:(1):548. doi:10.1038/s41467-019-08466-w 30602773
   PubMed Web of Science ®Google Scholar
• Peters AL , Buschur EO , Buse JB , et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium–glucose cotransporter 2 inhibition. Diabetes Care . 2015;38(9):1687–1693. doi:10.2337/dc15-0843 26078479
   PubMed Web of Science ®Google Scholar
• Fralick M , Schneeweiss S , Patorno E . Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med . 2017;376(23):2300–2302. doi:10.1056/nejmc1701990 28591538
   PubMed Web of Science ®Google Scholar
• Donnan JR , Grandy CA , Chibrikov E , et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open . 2019;9:1. doi:10.1136/bmjopen-2018-022577
   Web of Science ®Google Scholar
• Saad M , Mahmoud AN , Elgendy IY , et al. Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: a meta-analysis of placebo-controlled randomized trials. Int J Cardiol . 2017;228:352–358. doi:10.1016/j.ijcard.2016.11.181 27866027
   PubMed Web of Science ®Google Scholar
• Häring H-U , Merker L , Seewaldt-Becker E , et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care . 2014;37(6):1650–1659. doi:10.2337/dc13-2105 24722494
   PubMed Web of Science ®Google Scholar
• Kovacs CS , Seshiah V , Swallow R , et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obesity Metab . 2013;16(2):147–158. doi:10.1111/dom.12188
   Web of Science ®Google Scholar
• Storgaard H , Gluud LL , Bennett C , et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One . 2016;11:11. doi:10.1371/journal.pone.0166125
   Web of Science ®Google Scholar
• Hayashi T , Fukui T , Nakanishi N , et al. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol . 2017;16:1. doi:10.1186/s12933-016-0491-5 28057001
   PubMed Web of Science ®Google Scholar
• Pieber TR , Famulla S , Eilbracht J , et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obesity Metab . 2015;17(10):928–935. doi:10.1111/dom.12494
   PubMed Web of Science ®Google Scholar
• Briand F , Mayoux E , Brousseau E , et al. Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism. Diabetes . 2016;65(7):2032–2038. doi:10.2337/db16-0049 27207551
   PubMed Web of Science ®Google Scholar
• Zoppini G , Targher G , Chonchol M , et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care . 2011;35(1):99–104. doi:10.2337/dc11-1346 22028277
   PubMed Web of Science ®Google Scholar
• Chang Y-H , Lei -C-C , Lin K-C , et al. Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitus-a 4.6-year cohort study. Diabetes Metab Res Rev . 2015;32(6):557–564. doi:10.1002/dmrr.2768 26590369
   PubMed Web of Science ®Google Scholar
• Zhou Y , Fang L , Jiang L , et al. Uric acid induces renal inflammation via activating tubular NF-κB signaling pathway. PLoS One . 2012;7:6. doi:10.1371/journal.pone.0039738
   Web of Science ®Google Scholar
• Dekkers CCJ , Petrykiv S , Laverman GD , et al. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obesity Metab . 2018;20(8):1988–1993. doi:10.1111/dom.13301
   PubMed Web of Science ®Google Scholar
• Jabbour SA , Hardy E , Sugg J , et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care . 2013;37(3):740–750. doi:10.2337/dc13-0467 24144654
   PubMed Web of Science ®Google Scholar
• Bailey CJ , Gross JL , Hennicken D , et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med . 2013;11:1. doi:10.1186/1741-7015-11-43 23281898
   PubMed Web of Science ®Google Scholar
• Zhao Y , Xu L , Tian D , et al. Effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta‐analysis of randomized controlled trials. Diabetes Obesity Metab . 2017;20(2):458–462. doi:10.1111/dom.13101
   Web of Science ®Google Scholar
• Rosenwasser R , Sultan S , Sutton D , et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndrome Obesity . 2013:453–467. doi:10.2147/dmso.s34416
   Google Scholar
• Chino Y , Samukawa Y , Sakai S , et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos . 2014;35(7):391–404. doi:10.1002/bdd.1909 25044127
   PubMed Web of Science ®Google Scholar
• Wanner C , Inzucchi SE , Lachin JM , et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med . 2016;375(4):323–334. doi:10.1056/NEJMoa1515920 27299675
   PubMed Web of Science ®Google Scholar
• Mosenzon O , Wiviott SD , Cahn A , et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial. Lancet Diabetes Endocrinol . 2019;7(8):606–617. doi:10.1016/S2213-8587(19)30180-9 31196815
   PubMed Web of Science ®Google Scholar
• Perkovic V , Jardine MJ , Neal B , et al. Canagliflozin and Renal outcomes in type 2 diabetes and nephropathy. N Engl J Med . 2019;380(24):2295–2306. doi:10.1056/NEJMoa1811744 30990260
   PubMed Web of Science ®Google Scholar
• Herrington WG , Preiss D , Haynes R , et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J . 2018;11(6):749–761. doi:10.1093/ckj/sfy090 30524708
   PubMed Web of Science ®Google Scholar
• Ritesh J , U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Dapagliflozin Clinical Pharmacology Review (Report No. 202293). Silver Spring, MD: Division of Drug Information.
   Google Scholar
• Tang H , Dai Q , Shi W , Zhai S , Song Y , Han J . SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia . 2017;60(10):1862–1872. doi:10.1007/s00125-017-4370-8 28725912
   PubMed Web of Science ®Google Scholar
• Shaikh A . SGLT2 inhibitors and cancer: why further evidence is required. Diabetologia . 2017;60(12):2536–2537. doi:10.1007/s00125-017-4434-9 28905192
   PubMed Web of Science ®Google Scholar
• Dicembrini I , Nreu B , Mannucci E , et al. Sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors and cancer: a meta‐analysis of randomized controlled trials. Diabetes Obesity Metab . 2019. doi:10.1111/dom.13745
   Web of Science ®Google Scholar
• Washburn WN , Poucher SM . Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs . 2013;22(4):463–486. doi:10.1517/13543784.2013.774372
   PubMed Web of Science ®Google Scholar
• Cefalo CMA , Cinti F , Moffa S , et al. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovasc Diabetol . 2019;18:1. doi:10.1186/s12933-019-0828-y 30626440
   PubMed Web of Science ®Google Scholar
• Rieg JAD , Rieg T . What does sodium‐glucose co‐transporter 1 inhibition add: prospects for dual inhibition. Diabetes Obesity Metab . 2019;21(S2):43–52. doi:10.1111/dom.13630
   Web of Science ®Google Scholar
• Zambrowicz B , Freiman J , Brown PM , et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther . 2012;92(2):158–169. doi:10.1038/clpt.2012.58 22739142
   PubMed Web of Science ®Google Scholar
• Zambrowicz B , Lapuerta P , Strumph P , et al. LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion. Clin Ther . 2015;37:1. doi:10.1016/j.clinthera.2014.10.026 25592086
   PubMed Web of Science ®Google Scholar
• Garg SK , Henry RR , Banks P , et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med . 2017;377(24):2337–2348. doi:10.1056/nejmoa1708337 28899222
   PubMed Web of Science ®Google Scholar